Navigation Links
Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs
Date:4/21/2009

and VA111913 for dysmenorrhoea, product candidates which directly target the causes of conditions that together affect many millions of people, are poorly treated and represent billion dollar markets. Vantia was spun out from Ferring Research Ltd in 2008 and its pipeline is driven by the proven small molecule drug discovery and development capabilities of that unit and Vantia's experienced management team. Vantia's strategy is to develop candidates to Phase II proof-of-concept and then commercialise through partnerships. The Company is well-funded and backed by specialist life science investors MVM Life Science Partners, SV Life Sciences and Novo A/S.

http://www.vantiatherapeutics.com.

About VA106483 and nocturia:

VA106483 is a novel small molecule drug candidate in Phase II trials to treat nocturia, a common condition that causes sufferers to wake frequently during the night in order to urinate, thus interrupting sleep. VA106483 acts directly in the collecting ducts of the kidney by binding to vasopressin 2 receptors, decreasing urine volume. Clinical data indicate that VA106483 is generally well tolerated and an effective anti-diuretic that increases urine concentration and reduces urine output.

Vantia's initial indication for VA106483 is nocturia. A Phase II clinical programme has been designed and trials are underway, with initial results expected mid 2009.

Nocturia is commonly associated with benign prostatic hypertrophy (BPH) where it is estimated to affect up to 70% of BPH patients. With estimates putting the number of BPH/nocturia sufferers at 55 million in the seven largest markets world wide, and only 10% of these believed to be receiving any kind of treatment, it is a clear area of unmet medical need and estimated to be worth in excess of US$500m per annum. This market opportunity presents only part of
'/>"/>

SOURCE Vantia Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... Cambridge Semantics was one of just 22 companies ... Capitol Hill, hosted by The Data Transparency ... showcase how innovative data management applications can address the requirements ... , Originally introduced in 2011 by Committee Chairman ... Warner (D-VA ), the DATA Act is designed to ...
(Date:5/22/2013)... May 22, 2013   Oligomerix, Inc. , ... disease modifying therapeutics for Alzheimer,s disease (AD) and ... its Series B financing, which includes both issuance ... would represent approximately $2.8M in new investments in ... supported the raise. Funding from ...
(Date:5/22/2013)... 22, 2013  Superior Controls, Inc. has been ... Business NH Magazine.  For the past 22 years, ... distinguish themselves with extraordinary business and civic excellence. ... this honor," said Rick Pierro ... recognition, this award is a reflection of Superior ...
(Date:5/22/2013)... Switzerland (PRWEB) May 22, 2013 ... for industrial biotechnology, drug discovery, and life science ... Genedata Selector ™ as its bioinformatics platform ... production-relevant organisms. Genedata will provide AB Enzymes, one ... with a hosted solution of Genedata Selector accompanied ...
Breaking Biology Technology:Cambridge Semantics Underscores Need for Smart Data during “Data Demonstration Day” on Capitol Hill 2Oligomerix, Inc. Completes Series B Financing 2Oligomerix, Inc. Completes Series B Financing 3Superior Controls of Seabrook, NH named Business of the Year for 2013 by Business NH Magazine 2AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 2AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 3AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 4
... Calif., April 28 Sangamo,BioSciences, Inc. (Nasdaq: ... development,of novel zinc finger DNA-binding proteins (ZFPs) for ... of Thomas G.,Wiggans to the company,s Board of ... Chief Executive Officer of,Connetics Corporation, a biotechnology company, ...
... Mass., April 28 ChemDiv, Inc.,a global ... Syndexa Pharmaceuticals,Corporation, a biopharmaceutical company developing first-in-class ... announced today the signing,of a collaborative discovery ... ChemDiv will discover small molecule ligands for ...
... Group (NYSE: SCR ), a leading manufacturer ... the patented,anti-cancer biotech product Endu in China, today ... Trip, to be held May,6-10 and May 19-25 ... senior management will give a presentation at the ...
Cached Biology Technology:Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors 2Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors 3Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors 4Syndexa Pharmaceuticals Corporation and ChemDiv, Inc. Announce Discovery Collaboration 2Simcere Pharmaceutical Group to Participate in Credit Suisse 3rd Annual Healthcare Trip 2
(Date:5/21/2013)... Center today awarded 12 research grants, totaling nearly ... efforts. , The two-year grants of up to ... track the remediation of harmful algae blooms; assess ... plant invasions; study chromosomal damage in tree swallow ... , The grants were awarded to multidisciplinary teams ...
(Date:5/21/2013)... American Chemical Society (ACS), the world,s largest scientific ... National Meeting & Exposition, September 8-12, 2013, in ... Indiana Convention Center and at area hotels. , ... that span science,s horizons from astronomy to ... and online journalists a rich assortment of spot ...
(Date:5/21/2013)... -- Royal Philips Electronics (NYSE: PHG, AEX: PHIA) today ... with Philips, industry leading Live 3D TEE, now offers ... available Live 3D TEE and ICE will be shown ... official meeting for the European Association of Percutaneous Cardiovascular ... in 2012, Philips CX50 xMATRIX has been the only ...
Breaking Biology News(10 mins):U-M Water Center awards $570K in Great Lakes restoration grants 2U-M Water Center awards $570K in Great Lakes restoration grants 3U-M Water Center awards $570K in Great Lakes restoration grants 4Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2
... , SANTA ANA, Calif. and ISMANING, ... Inc., d.b.a. Identive Group (Nasdaq: INVE ; Frankfurt Stock ... the security, identification and RFID industries, today announced that it ... new executives in line with the announced reorganization of its ...
... LA JOLLA, CA-The neuropeptide corticotropin-releasing factor (CRF) makes ... is as the opening act in the stress response, ... at the Salk Institute for Biological Studies have found ... where it increases insulin secretion and promotes the division ...
... ability to stick to surfaces under wet conditions has ... fetal membranes, according to a recent Northwestern University study. ... in the fetal membrane can lead to the leakage ... of the pregnancy. Although some defects do repair themselves ...
Cached Biology News:Identive Group Expands Executive Management Team 2Identive Group Expands Executive Management Team 3Stress peptide and receptor may have role in diabetes 2Stress peptide and receptor may have role in diabetes 3Mussel-inspired 'glue' for fetal membrane repair 2
Based on Silica membrane matrix beads. The kit is designed for the purification of DNA (20 bp - 100 bp) from TAE/TBE agarose gels. Run time is approximately 45 minutes....
... DNA and Gel Band Purification Kit, 100. For ... and DNA fragments (0.1-10 kb) from solution and ... DNA fragments from solution in as little as ... in 15 min.Prepacked glass fiber matrix columns provide ...
These disposable button tethers are designed for rat infusion studies lasting more than 2 weeks. After one to two weeks the subcutaneous tissue will grow into the Dacron mesh, making the sutures irre...
Newborn Bovine Serum Heat-Inactivated...
Biology Products: